Literature DB >> 19381658

Classification and basic pathology of Alzheimer disease.

Charles Duyckaerts1, Benoît Delatour, Marie-Claude Potier.   

Abstract

The lesions of Alzheimer disease include accumulation of proteins, losses of neurons and synapses, and alterations related to reactive processes. Extracellular Abeta accumulation occurs in the parenchyma as diffuse, focal or stellate deposits. It may involve the vessel walls of arteries, veins and capillaries. The cases in which the capillary vessel walls are affected have a higher probability of having one or two apoepsilon 4 alleles. Parenchymal as well as vascular Abeta deposition follows a stepwise progression. Tau accumulation, probably the best histopathological correlate of the clinical symptoms, takes three aspects: in the cell body of the neuron as neurofibrillary tangle, in the dendrites as neuropil threads, and in the axons forming the senile plaque neuritic corona. The progression of tau pathology is stepwise and stereotyped from the entorhinal cortex, through the hippocampus, to the isocortex. The neuronal loss is heterogeneous and area-specific. Its mechanism is still discussed. The timing of the synaptic loss, probably linked to Abeta peptide itself, maybe as oligomers, is also controversial. Various clinico-pathological types of Alzheimer disease have been described, according to the type of the lesions (plaque only and tangle predominant), the type of onset (focal onset), the cause (genetic or sporadic) and the associated lesions (Lewy bodies, vascular lesions, hippocampal sclerosis, TDP-43 inclusions and argyrophilic grain disease).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19381658     DOI: 10.1007/s00401-009-0532-1

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  328 in total

1.  Pathway-specific alteration of synaptic plasticity in Tg2576 mice.

Authors:  Jung Hoon Jung; Kyongman An; Oh Bin Kwon; Hye-sun Kim; Joung-Hun Kim
Journal:  Mol Cells       Date:  2011-06-01       Impact factor: 5.034

Review 2.  Collapsin response mediator protein-2: an emerging pathologic feature and therapeutic target for neurodisease indications.

Authors:  Kenneth Hensley; Kalina Venkova; Alexandar Christov; William Gunning; Joshua Park
Journal:  Mol Neurobiol       Date:  2011-01-28       Impact factor: 5.590

3.  Association study of polymorphisms in the cyclooxygenase-2 gene and Alzheimer's disease risk in Chinese.

Authors:  Wenlu Tang; Meixia He; Bo Yang; Kankan Wei; Ming Yin; Lirong Zhang
Journal:  Neurol Sci       Date:  2012-05-24       Impact factor: 3.307

4.  Signalling in the genomic era.

Authors:  Vincenza Rita Lo Vasco
Journal:  J Cell Commun Signal       Date:  2010-06-06       Impact factor: 5.782

5.  Dendritic degeneration, neurovascular defects, and inflammation precede neuronal loss in a mouse model for tau-mediated neurodegeneration.

Authors:  Tomasz Jaworski; Benoit Lechat; David Demedts; Lies Gielis; Herman Devijver; Peter Borghgraef; Hans Duimel; Fons Verheyen; Sebastian Kügler; Fred Van Leuven
Journal:  Am J Pathol       Date:  2011-08-10       Impact factor: 4.307

Review 6.  Inhibition of protein misfolding and aggregation by natural phenolic compounds.

Authors:  Zohra Dhouafli; Karina Cuanalo-Contreras; El Akrem Hayouni; Charles E Mays; Claudio Soto; Ines Moreno-Gonzalez
Journal:  Cell Mol Life Sci       Date:  2018-07-20       Impact factor: 9.261

7.  MA-[D-Leu-4]-OB3, a small molecule synthetic peptide leptin mimetic, improves episodic memory, and reduces serum levels of tumor necrosis factor-alpha and neurodegeneration in mouse models of Type 1 and Type 2 Diabetes Mellitus.

Authors:  Zall Hirschstein; Gautam Reddy Vanga; Guirong Wang; Zachary M Novakovic; Patricia Grasso
Journal:  Biochim Biophys Acta Gen Subj       Date:  2020-07-29       Impact factor: 3.770

Review 8.  Challenges of multimorbidity of the aging brain: a critical update.

Authors:  Kurt A Jellinger; Johannes Attems
Journal:  J Neural Transm (Vienna)       Date:  2014-08-05       Impact factor: 3.575

Review 9.  The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases.

Authors:  Filippo Baldacci; Sonia Mazzucchi; Alessandra Della Vecchia; Linda Giampietri; Nicola Giannini; Maya Koronyo-Hamaoui; Roberto Ceravolo; Gabriele Siciliano; Ubaldo Bonuccelli; Fanny M Elahi; Andrea Vergallo; Simone Lista; Filippo Sean Giorgi; Harald Hampel
Journal:  Expert Rev Mol Diagn       Date:  2020-02-27       Impact factor: 5.225

Review 10.  Targeting Tumor Necrosis Factor Alpha for Alzheimer's Disease.

Authors:  Boris Decourt; Debomoy K Lahiri; Marwan N Sabbagh
Journal:  Curr Alzheimer Res       Date:  2017       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.